A Study of LY2140023 in Healthy Participants

Stopped The decision to stop the trial was based on efficacy results in the overall schizophrenia patient population.

Conditions

• Healthy Participants

Interventions

• DRUG: LY2140023

Sponsor

Denovo Biopharma LLC